Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab for Giant Cell Arteritis (TitAIN)
NCT03765788Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2019
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in giant cell arteritis (GCA) comparing Secukinumab with Placebo (2 arms). Primary endpoint: Percentage of Participants in Sustained Remission Until Week 28. Started Jan 2019; status: completed.
02
Drugs
secukinumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on NCT03765788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03765788.